NEW YORK, NEW YORK - OCTOBER 03: In this photo illustration, a medical syringe and vials of the Pfizer US pharmaceutical corporation and BioNTech German biotechnology 2021 company logos are seen on October 03, 2021 in New York City. Pfizer and BioNTech announced its conclude phase 3 study of COVID-19 vaccine candidate with 95% primary efficacy analysis, as the media reported on 18 November 2020. (Photo Illustration by Cindy Ord/Getty Images for Pfizer/BioNTech)

(AP) – Pfizer says three small doses of its COVID-19 vaccine protect kids under 5. The company released preliminary results on Monday and said it plans to give the data to U.S. regulators later this week. It’s the latest step toward letting the littlest kids get the shots. The 18 million tots under 5 are the only group in the U.S. not yet eligible for COVID-19 vaccination. The Food and Drug Administration has begun evaluating data from rival Moderna. That company hopes to offer two kid-sized shots by summer. The FDA has set tentative dates next month for its scientific advisers to publicly debate data from Pfizer and Moderna.